Pfizer hemophilia drug marstacimab is approved by FDA
Whew. Pfizer — after a week in which it began a showdown with an activist investor, was betrayed by and then reunited with two former top executives, and ended work on an RSV drug — finally has some...
View ArticlePfizer's situation with Starboard; Meet Endpoints' 2024 Women in Biopharma;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleEli Lilly obesity drug may go back on shortage, FDA says, in win for...
The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a trade group representing large compounding pharmacies challenged the move. A...
View ArticleClik here to view.
Transgene shares dip as therapeutic cancer vaccine disappoints in Phase 2 trial
Transgene’s therapeutic cancer vaccine candidate has failed a mid-stage test in certain HPV-driven cancers, sending its shares down around 14% Monday morning. The French biotech’s TG4001 plus Merck...
View ArticleClik here to view.
Catalent sells New Jersey plant to Belgian CDMO, plans moving HQ elsewhere
Novo Holdings is set to buy one less facility from Catalent as the manufacturer has sold a facility in New Jersey to a European CDMO. The sale also means Catalent is looking for a new corporate...
View ArticleShift Bioscience raises $16M to find genes that rewind epigenetic clock
Seven years ago, Daniel Ives believed that he was on the cusp of solving aging. He wanted to continue working on a discovery he made as a graduate student at the University of Cambridge, but couldn’t...
View ArticleClik here to view.
Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3...
Danish drugmaker Lundbeck will buy La Jolla, CA-based Longboard Pharmaceuticals for $2.6 billion in cash, the companies said Monday morning, marking the largest biopharma M&A deal since July....
View ArticleClik here to view.
Mark Pruzanski gets another shot at MASH, joining as chair of Inventiva as it...
After flashing warning signs in July with only enough money for that month, Inventiva has now secured a lifeline to keep its Phase 3 liver disease study afloat. The French biotech said Monday it got...
View ArticleNovartis ends mid-stage IPF trial, will keep testing drug in PAH
Novartis has terminated a mid-stage trial of an oral treatment candidate for idiopathic pulmonary fibrosis, the company confirmed to Endpoints News. The Swiss pharma giant axed a Phase 2 study of...
View ArticleEndpoints AI coverage: Come hear from two Nobel winners at our events
More than a year ago, Endpoints News made the decision that we needed a dedicated reporter covering the use of artificial intelligence in drug R&D. Since then, our senior correspondent Andrew Dunn...
View ArticleAkeso raises $250M; SalioGen’s layoffs
Plus, news about Nicox, Soleus and Molecular Templates: Akeso Biopharma’s $250M placement: The Hong Kong-based company, which is developing a closely watched bispecific antibody with Summit...
View ArticleJasper shares rally as chronic hives drug scores in small, early trial
Jasper Therapeutics’ anti-c-KIT antibody has shown promise in a Phase 1b/2a test in people with certain irritable skin conditions, sending its shares rising on Monday. Fourteen out of 15 participants...
View ArticlePfizer details results from failed Phase 3 trial of Duchenne muscular...
The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant functional benefit one year after receiving the therapy despite the...
View ArticleClik here to view.
GSK touts data from two late-stage trials with long-acting drug in chronic...
GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this time in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Both...
View ArticleTPG and Blackstone working on bid to buy eye care company Bausch + Lomb — report
Private equity firms TPG and Blackstone are working on a potential deal to buy Brent Saunders-led eye care company Bausch + Lomb, the Financial Times reports. Citing “people familiar with the matter,”...
View ArticleEli Lilly reveals £279M investment in the UK through new government deal
Eli Lilly plans to invest £279 million ($364 million) in the UK as part of a new government partnership in which the drugmaker will bring its Gateway Labs overseas for the first time. The...
View ArticleNovartis used a PRV to speed Kisqali's latest indication, FDA says
Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, the FDA said Monday. The FDA did not disclose where this PRV came to Novartis...
View ArticleNovo Nordisk files 18 lawsuits against GLP-1 compounders in 44 days
Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo Nordisk and Eli Lilly have launched legal campaigns against medical spas,...
View ArticleClik here to view.
Forbion raises €2.1B for two new biotech funds after series of company exits
Dutch biotech investor Forbion has raised two new funds to put into biotech companies, just 18 months after its last major raise and following a series of successful exits in its portfolio. The new...
View ArticleBiotech tools company Nuclera raises $75M for protein manufacturing tech
Protein production company Nuclera has raised a $75 million Series C to continue to bring its manufacturing platform to market next January after a soft launch in May. “This is a perfect time to start...
View Article